We are live on
!
Find out more
IDXG
Interpace Biosciences, Inc. Common Stock
IDXG
IDXG
Delisted
IDXG was delisted on the 24th of February, 2021.
12 hedge funds and large institutions have $849K invested in Interpace Biosciences, Inc. Common Stock in 2020 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 7 closing their positions.
New
Increased
Maintained
Reduced
Closed
33% less funds holding
Funds holding: 18 → 12 (-6)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
60% less capital invested
Capital invested by funds: $2.14M → $849K (-$1.29M)
86% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 7
Holders
12
Holders Change
-6
Holders Change %
-33.33%
% of All Funds
0.21%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
1
Reduced
2
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$38.1K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$6.34K |
Top Sellers
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$880K |
| 2 |
PM
Penbrook Management
New York
|
-$261K |
| 3 |
MFG
Magnus Financial Group
New York
|
-$150K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$37K |
| 5 |
Squarepoint
New York
|
-$14.5K |